首页> 外文期刊>Gastroenterology Research >Efficacy of Gastric Electrical Stimulation for Gastroparesis: US/European Comparison
【24h】

Efficacy of Gastric Electrical Stimulation for Gastroparesis: US/European Comparison

机译:胃电刺激对胃轻瘫的疗效:美国/欧洲的比较

获取原文
       

摘要

Background: Gastric electrical stimulation (GES) is used in both the US and Europe, but little research has investigated the demographics of gastroparesis patients receiving GES by geographic location. Methods: We compared data from 380 patients, 296 female and 84 males, mean age 42 years, 246 idiopathic (ID), 107 diabetic (DM), and 27 post-surgical (PS). The statistical significance was calculated by Chi-square test and a P-value obtained for ID, DM, and PS. The statistical significance was calculated by Fischer exact test and a P-value obtained comparing male vs. female. Results: European centers had 61 GES patients compared to 319 from the US. In Europe, 100% of patients had gastric emptying test (GET) values available; in the US, it was 75% of patients. European centers had more DM patients (59%) than the US (22%), and a smaller proportion of ID patients (25%) than the US (72%). There was a statistical difference between the causes of gastroparesis in the patients receiving GES (P-value 0.00001). There was also significant difference in the gender of the patients receiving GES, with a greater proportion of women in the US (P value = 0.0023). Conclusions: Comparing GES in US vs. Europe demonstrated significant differences in gastroparesis demographics and percentage of patients with GET data. After analyzing the previously discussed results and reviewing recent updates in evidence-based medicine guidelines, the discrepancy and variance in patient populations in the US and Europe emphasizes the need for a database that allows better analysis and treatment of gastroparesis patients worldwide including stimulation therapies.
机译:背景:在美国和欧洲都使用了胃电刺激(GES),但很少有研究按地理位置调查接受GES的胃轻瘫患者的人口统计资料。方法:我们比较了380例患者的数据,其中296例女性和84例男性,平均年龄42岁,246例特发性(ID),107例糖尿病(DM)和27例手术后(PS)。通过卡方检验计算统计显着性,并获得ID,DM和PS的P值。通过Fischer精确检验计算统计学显着性,并比较男性和女性获得P值。结果:欧洲中心有61名GES患者,而美国有319名。在欧洲,有100%的患者具有可用的胃排空测试(GET)值;在美国,这一比例为75%。欧洲中心的DM患者(59%)比美国(22%)多,而ID患者(25%)的比例比美国(72%)小。在接受GES的患者中,胃轻瘫的原因之间存在统计学差异(P值<0.00001)。接受GES的患者在性别上也存在显着差异,在美国女性中比例更高(P值= 0.0023)。结论:比较美国和欧洲的GES显示胃轻瘫人口统计学和GET数据患者的百分比存在显着差异。在分析了先前讨论的结果并回顾了循证医学指南的最新进展之后,美国和欧洲患者人群的差异和差异强调需要建立一个数据库,以便更好地分析和治疗全世界的胃轻瘫患者,包括刺激疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号